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Abstract
Introduction: Clara cell protein 10 (CC-10) has been associated with inflammatory and infectious pulmonary
diseases. This study evaluates CC-10 concentrations in bronchoalveolar lavage (BAL) fluid as a potential marker of
ventilator-associated pneumonia (VAP).
Methods: Between January 2003 and December 2007, BAL fluid samples obtained from critically ill patients at the
intensive care unit of the Maastricht University Medical Centre clinically suspected of having VAP were included.
Patients were divided into two groups: (1) microbiologically confirmed VAP (the VAP group) and (2)
microbiologically unconfirmed VAP (the non-VAP group). The concentration of CC-10 was measured by means of a
commercially available enzyme-linked immunosorbent assay kit, and retrospective analysis was performed. Areas
under the curve of receiver operating characteristic curves were calculated for CC-10 concentrations.
Results: A total of 196 patients (122 men, 74 women) were included. A total of 79 (40%) of 196 cases of suspected
VAP were microbiologically confirmed. The median CC-10 concentration in the VAP group was 3,019 ng/mL (range,
282 to 65,546 ng/mL) versus 2,504 ng/mL (range, 62 to 30,240 ng/mL) in the non-VAP group (P = 0.03). There was
no significant difference in CC-10 concentrations between patients treated with or without corticosteroids (P =
0.26) or antibiotic therapy (P = 0.9). The CC-10 concentration did not differ significantly between patients with
Gram-positive versus Gram-negative bacteria that caused the VAP (P = 0.06). However, CC-10 concentrations did
differ significantly between the late-onset VAP group and the non-VAP group.
Conclusions: The CC-10 concentration in BAL fluid yielded low diagnostic accuracy in confirming the presence
of VAP.
Introduction
Clara cell protein 10 (CC-10) is a low-molecular-weight
protein secreted into the alveoli in large quantities by
nonciliated Clara cells [1,2]. CC-10 has structural homol-
ogy with rabbit uteroglobin, which has immunosup-
pressive, anti-inflammatory, antiprotease and anti-
phospholipase A2 activities [1,3,4]. This profile suggests a
possible anti-inflammatory role for human CC-10 [4]. In
line with these findings, differences in serum CC-10 con-
centrations have been demonstrated in several inflamma-
tory lung diseases. Bronchial asthma and chronic
eosinophilic pneumonia (CEP) have been associated with
decreased serum CC-10, while patients with idiopathic
interstitial pneumonia (IIP) demonstrated increased
levels of CC-10 in serum and bronchoalveolar lavage
(BAL) fluid [4]. Moreover, some studies in which pul-
monary infectious diseases were investigated have sug-
gested that CC-10 activity is influenced by the type of
microorganism which is isolated. Pseudomonas aerugi-
nosa has been shown to decrease CC-10 promoter activ-
ity, leading to a decrease in CC-10 mRNA and eventually
to a decrease in the concentration of CC-10 [5,6]. The
microscopic examination of BAL fluid is appreciated for
various clinical applications. It is routinely used in the
assessment of interstitial lung diseases, suspected cases of
ventilator-associated pneumonia (VAP) and opportunis-
tic lung infections [7-10]. VAP frequently develops in
patients who are on mechanical ventilation in the inten-
sive care unit (ICU) and is associated with high costs,
morbidity and mortality, especially when treatment is
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with VAP are S. aureus, P. aeruginosa and the Enterobac-
teriaceae [13]. Unfortunately, the differentiation between
VAP and noninfectious respiratory conditions mimicking
VAP is difficult, and the culture of BAL fluid takes up to
48 hours. Microscopic examination of BAL fluid can be
helpful in distinguishing VAP from noninfectious condi-
tions mimicking VAP [14]. The differential cell count,
especially the percentage of cells with intracellular organ-
isms (ICOs), can be helpful in the diagnosis of VAP [14].
Furthermore, the percentage of ICOs is not influenced by
antibiotic therapy in the 72 hours prior to the BAL. This
makes it an important parameter for distinguishing VAP
from non-VAP conditions [15]. However, BAL fluid
workup and its microscopic analysis are time-consuming
and must be done by experienced technicians. Therefore,
different biological markers (for example, soluble trigger-
ing receptor expressed on myeloid cells (sTREM-1), pro-
calcitonin, C-reactive protein) have been proposed as
candidates for a rapid diagnostic test for VAP, but all
failed to sufficiently discriminate VAP from other
respiratory conditions mimicking VAP [16-20]. Procalci-
tonin, C-reactive protein and sTREM-1 were previously
investigated by our group in the same patient population
as the one in the present study. However, these markers
could not accurately distinguish VAP from other respira-
tory conditions mimicking VAP [16,17]. Because of the
possible anti-inflammatory role of CC-10, we hypothesise
that CC-10 concentrations may be increased in patients
with VAP. Therefore, the present study was designed to
evaluate CC-10 in BAL fluid as a potential marker of
VAP in critically ill patients in whom VAP is suspected.
Materials and methods
Sampling technique
This study was performed at the 17-bed general ICU of
the University Hospital Maastricht (Maastricht, the
Netherlands). During a 59-month period (January 2003
to December 2007), we considered consecutive BAL
f l u i ds a m p l e so b t a i n e df r o mp a t i e n t sw h oh a du n d e r -
gone mechanical ventilation for more than 48 hours and
were clinically suspected of having pneumonia. Only the
first episode of VAP was included. Clinical suspicion of
VAP was based on the criteria described by Bonten
et al. [8] (Table 1). Bronchoscopies with BAL were per-
formed as previously described [21,22]. In short, chest
X-rays were performed to identify the affected lung seg-
ment. In those cases in which the affected segment
could not be reached and in cases of patients with gen-
eral opacification, the lingula was sampled. Bronchosco-
pies and subsequent lavage were performed prior to
new antibiotic treatment and by experienced pulmonary
physicians. Four fractions of 50 mL each of sterile saline
(0.9% NaCl at room temperature) were instilled into the
affected subsegmental bronchus and immediately aspi-
rated and recovered. The BAL fluid samples were trans-
ported to the laboratory within 15 minutes of collection
and were analysed immediately upon arrival in the
laboratory.
Laboratory processing
The first fraction of BAL fluid representing the bron-
chial fraction was not used in this study. The remaining
three fractions (alveolar fractions) were pooled and
processed as previously described [23,24]. The bronch-
oalveolar lavage fluid workup included total cell count,
differential cell count and quantitative culture for bac-
teria and yeasts. On the basis of clinical suspicion, addi-
tional diagnostic tests were added, such as culture for
filamentous fungi, Mycobacteria spp. and Legionella
spp., as well as polymerase chain reactions for the detec-
tion of Chlamydophyla pneumoniae, Mycoplasma pneu-
moniae and viruses.
Exclusion criteria
Bronchoalveolar lavage fluid samples were excluded if
(1) the recovered volume was less than 20 mL; (2) the
total cell count was less than 60,000 cells/mL; (3) exces-
sive amounts of intercellular debris, red blood cells or
damaged red blood cells were present; or (4) more than
1% squamous epithelial cells were present [17]. In a
small percentage (< 5%) of patients suspected of having
VAP, BAL could not be performed because of a high
risk of severe complications and/or a high risk of death.
Criteria for not performing a BAL are (1) fraction of
inspired oxygen > 65% and (2) severe right-sided heart
failure. A high level of positivee n d - e x p i r a t o r yp r e s s u r e
or a low thrombocyte count was not considered an
exclusion criteria.
This study was approved by the institutional review
board and the ethics committee of the Maastricht Uni-
versity Medical Centre, and informed consent was
obtained from patients or their next of kin.
Table 1 Criteria for clinical suspicion of ventilator-
associated pneumonia
a
Criteria
I. At least three positive results of the following four criteria
1. Rectal temperature > 38°C or < 35.5°C
2. Blood leucocytosis (> 10 × 10³/mm³) and/or left shift of blood
leucopenia (< 3 × 10³/mm³)
3. > 10 leukocytes per high-power magnification field in Gram stain
of tracheal aspirate
4. Positive culture from tracheal aspirate
II. New, persistent progressive infiltrate visualised on chest radiograph
aThe diagnosis of clinical suspicion of ventilator-associated pneumonia was
made when criteria I and II were positive. The criteria listed here are as
described by Bonten et al.[8].
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VAP was microbiologically confirmed if BAL fluid cultures
yielded ≥ 10
4 colony-forming units (CFU)/mL and/or
microscopic analysis revealed ≥ 2% intracellular organisms
[17]. In the case of mixed infections, either (1) one single
microorganism had to yield a concentration of ≥ 10
4 CFU/
mL or (2) the sum of the different microorganisms had to
be ≥ 10
4 CFU/mL. According to these criteria, patients
were divided into two groups: (1) microbiologically con-
firmed VAP (the VAP group) and (2) microbiologically
unconfirmed VAP (the non-VAP group). Early-onset VAP
was defined as VAP occurring within 7 days after intuba-
tion, whilst late-onset VAP was defined as VAP occurring
more than 7 days after intubation [13,25].
Collection of clinical data
Collected data included patients’ demographic charac-
teristics, such as age and gender, as well as clinical data,
such as reason for ICU admission, length of ICU stay
before BAL, total length of stay at ICU, total length of
mechanical ventilation, total length of hospital stay,
mortality, alternative pulmonary diagnosis (non-VAP
group) and alternative infectious diagnosis (non-VAP
group).
Determination of CC-10 concentration in BAL fluid
CC-10 concentration in the cell-free supernatant of BAL
fluid was determined in duplicate by using a commer-
cially available enzyme-l i n k e di m m u n o s o r b e n ta s s a y
(ELISA) kit (Biovendor Inc., Brno, Czech Republic). The
ELISA was performed according to the manufacturer’s
instructions.
Quality control of CC-10 concentration in BAL fluid
BAL fluid samples were spiked with a positive control to
test for spike recovery.
Urea concentration analysis
All concentrations of CC-10 were corrected for the dilu-
tion factor of the BAL fluid. To compare the concentra-
tions of CC-10 in the BAL fluid samples, the levels were
converted to concentrations in the epithelial lining fluid
(ELF) by using the urea concentrations in BAL fluid and
serum. Therefore, the following formula by Wiedermann
et al.[26] was used:
[X]ELF = ([X]BAL fluid × urea serum)/urea BAL
fluid concentration in which [X] stands for the con-
centration of CC-10.
In this article, this concentration is referred to as the
concentration in BAL fluid. Urea concentrations in serum
and BAL fluid were assessed by using a commercially
available kit (Urease Method; Beckman Coulter, Fuller-
ton, CA, USA). Urea in both serum and BAL fluid was
measured using a Synchron LX20 analyser (Beckman
Coulter).
Statistical analyses
All CC-10 concentrations were logarithmically trans-
formed to obtain normally distributed CC-10 concentra-
tions in the samples. To compare differences in
concentrations of CC-10 between the non-VAP and
VAP groups, an independent sample t-test was used
(significance was set at 0.05). For comparison between
early- and late-onset VAP, one-way analysis of variance
was used (significance was set at 0.05), followed by
aB o n f e r r o n ipost hoc test. To ascertain the value of
CC-10 in BAL fluid for the diagnosis of VAP, areas
under the curve (AUC) of receiver operating characteris-
tic curves were calculated. The statistical analysis
was performed using SPSS software version 16.0 for
Windows (SPSS, Chicago, IL, USA).
Results
Patients included in the study
Between January 2003 and December 2007, 383 BAL
fluid samples were eligible for inclusion in this study.
A total of 187 BAL fluid samples were excluded for the
following reasons: (1) lack of material (40 BAL fluid
samples), (2) not the first episode of suspected VAP in
that patient (77 BAL fluid samples), or (3) the fluid sam-
ple fitted the exclusion criteria (70 BAL fluid samples).
Of the latter 70 samples, 18% were excluded because of
poor quality (excessive debris, large percentage of
epithelial cells present), 16% were excluded because of a
recovered volume < 20 mL and 66% were excluded
because of a low total cell count (< 60,000 cells/mL).
A total of 196 patients (122 men, 74 women) with a
clinical suspicion of VAP were included in the study.
Of the 196 episodes of suspected VAP, 79 (40%) were
microbiologically confirmed (Figure 1). The patients’
characteristics are shown in Table 2. The median age of
patients in the VAP group was 64 years (range, 19-84
years) compared with 61 years (range, 18-87 years) in
the non-VAP group. Table 3 shows the microorganisms
involved in the microbiologically confirmed cases of
VAP and in the non-VAP cases. Table 4 shows the
alternative pulmonary and infectious diagnoses in the
patients included in the VAP group.
Spiking recovery of CC-10 in BAL fluid
BAL fluid samples were spiked with different amounts
of CC-10. The recovery of the spike reached 92%. Both
the low and high concentrations of spiked CC-10 had
the highest recovery rates.
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The median CC-10 concentration of the VAP group was
3,019 ng/mL (range, 282-65,546 ng/mL) versus 2,054
ng/mL (range, 62-30,240 ng/mL) in the non-VAP group
(P = 0.03; 95% confidence interval (95% CI), 0.025-
0.380) (Figure 2), with an AUC of 0.586 (P = 0.06; 95%
CI, 0.496-0.676) (Figure 3). Therefore, the CC-10 levels
were not discriminative for VAP. All analyses were also
conducted using the uncorrected CC-10 concentrations.
However, after logarithmic transformation, these con-
centrations remained non-normally distributed. For this
reason, a Mann-Whitney U test was used, which
resulted in a P value of 0.254 (95% CI, 0.461-0.638])
(data not shown).
CC-10 concentration in early- and late-onset VAP
The CC-10 concentration between early- and late-onset
VAP showed no statistical significance. However, when
the non-VAP group was compared with the late-onset
VAP group, a significant difference was observed (P =
0.04), with an AUC of 0.62 (P = 0.29; 95% CI, 0.518-
0.731). When the non-VAP group was further divided
on the basis of the days of intubation before BAL, no
significant difference was observed between the late-
onset VAP group and the non-VAP group intubated for
more than 7 days (P = 0.171; 95% CI, -0.734-0.402).
However, a significant difference could be detected
between patients with late-onset VAP and non-VAP
patients intubated for less than 7 days before BAL (P =
0.04; 95% CI, 0.014-0.544).
CC-10 concentrations in the VAP subgroups versus the
non-VAP group
On the basis of the previously described results, the
VAP group was subdivided based on the causative
organism. Dividing the VAP group into Gram-positive
(median, 3.238; and interquartile range (IQR), 0.786)
and Gram-negative (median, 3.529; IQR, 1.007) causative
organisms yielded no significant result (P = 0.06).
Analysis of the VAP group was also performed using
the following classification of causative organisms found:
nonfermenters (for example, P. aeruginosa, Acinetobac-
ter spp.), Staphylococcus spp., Streptococcus spp., Entero-
bacteriaceae (for example, Escherichia coli, Klebsiella
spp., Proteus spp.), a group in which BAL fluid analysis
yielded multiple microorganisms and a group of other
causative organisms (for example, Candida spp., Hae-
mophilus spp.). No significant differences in CC-10 con-
centrations between the different groups and the non-
VAP group (P = 0.26) were found (Figure 4).
Figure 1 Inclusion flowchart. *Percentage between brackets.
Table 2 Patient characteristics
a
Parameter VAP Non-VAP P value
Number of patients 79 117
Mean age in years (range) 60 (19-84) 58 (18-87) 0.445
Male:female ratio 1.6:1 1.7:1 0.887
Mortality rate (%) 44 36 0.324
Median hospital stay in days (range) 47 (7-540) 47 (6-297) 0.289
Median ICU stay in days (range) 43 (6-484) 46 (1-291) 0.454
Median days of intubation (range) 8 (1-172) 8 (1-198) 0.289
Reason for admission, number of patients (%)
Cardiac 6 (7.6) 12 (10.3)
Pulmonary 14 (17.8) 27 (23.1)
Trauma 14 (17.8) 15 (12.8)
Surgery 17 (21.5) 15 (12.8)
Neurological 10 (12.6) 6 (5.1)
Malignancy 5 (6.3) 9 (7.7)
Vascular surgery 6 (7.6) 19 (16.2)
Other 7 (8.3) 14 (12.0)
Median Clara cell protein concentration in ng/mL (range) 3,019 (282-65,546) 2,504 (62-30,240) 0.03
aVAP, ventilator-associated pneumonia; ICU, intensive care unit.
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concentration
The CC-10 concentrations were compared between the
VAP and non-VAP groups on the basis of the category
of diagnosis made on ICU admittance: cardiac, pulmon-
ary, traumatic, surgical, neurological and other. No sig-
nificant differences were observed between the VAP and
non-VAP groups (Table 1).
Antibiotic and corticosteroid therapy at the time of BAL
At the time of BAL, there was no significant difference
in CC-10 concentrations between patients with or
Table 3 Microorganisms involved in episodes of VAP and non-VAP
a
Microorganism VAP n (%) Early-onset VAP n (%) Late-onset VAP n (%) Non-VAP n (%)
Pseudomonas aeruginosa 12 (14) 4 (11) 8 (20) 11 (9)
Staphylococcus aureus 11 (13) 7 (17) 2 (5)
Escherichia coli 5 (6) 3 (8) 1 (2) 2 (2)
Proteus spp. 1 (1) 1 (2)
Klebsiella spp. 7 (9) 6 (16) 2 (5)
Stenotrophomonas maltophilia 2 (3)
Moraxella catharrhalis 1 (1) 1 (3) 2 (5)
Serratia spp. 3 (4) 1 (3) 2 (5)
Enterobacter spp. 3 (4) 1 (3) 2 (5)
Haemophilus spp. 6 (8) 4 (11)
Mixed 17 (21) 7 (17) 10 (24) 3 (2.5)
Other 11 (13) 4 (11) 7 (17)
No growth 101 (86.5)
Total (n) 79 38 41 117
aVAP, ventilator-associated pneumonia.
Table 4 Alternative pulmonary and infectious diagnoses
in patients included in the non-VAP group
a
Alternative diagnoses Patients n (%)
Alternative pulmonary diagnosis
Acute respiratory distress syndrome 25 (21)
Congestive heart failure 20 (17)
Diffuse alveolar damage 9 (8)
Idiopathic pulmonary fibrosis 5 (4)
Autoimmune disease 4 (3)
Pulmonary contusion 3 (2.5)
Pulmonary oedema of unknown origin 3 (2.5)
Eosinophilic pneumonia 2 (1.5)
Pneumocystis pneumonia 2 (1.5)
Bronchiolitis obliterans with organizing pneumonia 1 (1)
Drug-induced pneumonia 1 (1)
Chronic obstructive pulmonary disease 1 (1)
Sarcoidosis 1 (1)
Aspergillus fumigatus infection 1 (1)
Legionella pneumophila infection 1 (1)
No diagnosis 16 (14)
No pulmonary disease 22 (19)
Total (n) 117
Alternative infectious diagnosis
Intravenous catheter-related infection 7 (6)
Urosepsis 5 (4)
Peritonitis 2 (1.5)
Mediastinitis 2 (1.5)
Encephalitis 1 (1)
Abdominal abscess 1 (1)
No infectious focus found 99 (85)
Total (n) 117
aVAP, ventilator-associated pneumonia.
Figure 2 Comparison of the Clara cell protein concentration
between the ventilator-associated pneumonia (VAP) and the
non-VAP groups. Concentrations are given on a logarithmic scale.
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CI, -0.488-0.131) or between patients with or without
antibiotic therapy (P = 0.909; 95% CI, -0.192-0.215)
(data not shown).
Discussion
The present study shows no correlation between the
concentration of CC-10 in BAL fluid and the presence
of VAP. Furthermore, CC-10 levels in BAL fluid were
not associated with the isolated microorganism.
Previous studies showed that CC-10 concentration in
either serum or BAL fluid may be increased in some
patients with pulmonary inflammation, for example, due
to exposure to lung irritants such as smoke from open
f i r e s[ 2 7 ] ,a sw e l la si np a t i e n t sw i t ha c u t el u n gi n j u r y
and patients with pulmonary fibrosis or sarcoidosis [28].
In contrast to these findings, other types of pulmonary
inflammation, such as in patients who have had chronic
exposure to tobacco smoke [29,30], as well as in lung
transplant recipients with bronchiolitis obliterans and
airway neutrophilia [31], have been associated with
decreased CC-10 concentration. A study of acute lung
injury induced by lipopolysaccharides in rats showed
alterations in CC-10 cells [32], which suggests an invol-
vement of CC-10 cells in the inflammatory process
induced by bacterial pulmonary infection.
Ye et al.[4] measured the concentration of CC-10 in
the sera of patients with a variety of pulmonary diseases,
including community-acquired pneumonia (CAP). These
authors revealed a high CC-10 concentration in patients
with IIP and a low CC-10 concentration in patients with
CEP and bronchial asthma. However, in patients with
sarcoidosis, COPD and CAP, no differences in CC-10
concentration compared with healthy controls were
found. Unfortunately, the concentration of CC-10 was
measured in serum instead of BAL fluid, and a limited
number of patients were included (CAP, n =9 ;C E P ,
n = 6; IIP, n = 11; COPD, n = 13; sarcoidosis, n = 22).
To the best of our knowledge, the present study is the
first in which the value of CC-10 concentration in BAL
fluid as a potential marker for VAP has been evaluated.
In the present study, the CC-10 concentration was not a
useful marker for differentiating VAP from non-VAP,
regardless of the type of microorganism causing the
patient’s pneumonia or the reason for hospitalisation.
However, the CC-10 concentration was useful in distin-
guishing late-onset VAP from non-VAP. A number of
possible explanations should be considered. First of all,
the type of microorganisms associated with late-onset
VAP may be influential. One of the microorganisms fre-
quently associated with late-onset VAP is P. aeruginosa
[13,25,33]. P. aeruginosa is known to produce numerous
virulence factors which can destroy the host defence
mechanism and facilitate lung infection [25,34]. Harrod
et al.[5] and Hayashida et al.[6], found a decrease in
CC-10 expression in cases of P. aeruginosa pulmonary
infection. Interestingly, the present study did not show a
difference in CC-10 concentration when the infection
was caused by P. aeruginosa. However, the other studies
mentioned were based on mouse model experiments
[5,6], whilst the present study included ICU patients.
Since Clara cell size, mitochondrial morphology, distri-
bution of endoplasmic reticulum and number of Clara
cells present in the lung vary between species [35-37],
Figure 3 Receiver operating characteristic for the Clara cell
protein concentration. P value, 0.06; 95% confidence interval,
0.496-0.679.
Figure 4 Comparison of the Clara cell protein concentration
between the non-VAP group and the VAP group divided on
the basis of the causative organism group. Concentrations are
given on a logarithmic scale.
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results derived from studies in humans. By dividing the
VAP group into different subgroups on the basis of the
causative organism, the number of patients belonging to
each group was relatively small. The number of patients
with VAP caused by P. aeruginosa in the present study
may thus be too small to reach statistical significance.
A tendency towards significance was observed when the
VAP group was subdivided into Gram-positive and
Gram-negative causative organisms and compared with
the non-VAP group. CC-10 levels were slightly higher
in the BAL fluid samples of patients with confirmed
Gram-negative VAP. Since Gram-negative microorgan-
isms (especially P. aeruginosa) are the major cause of
late-onset VAP, the explanations mentioned in the pre-
vious section may also be attributed to this tendency
towards significance. The second explanation for the
fact that CC-10 concentrations distinguished late-onset
VAP from non-VAP may be the duration of mechanical
ventilation. Dhanireddy et al.[38] found that the combi-
nation of mechanical ventilation and bacterial infection
resulted in increased pulmonary and systemic inflamma-
tion. Mechanical ventilation itself may at least partly be
responsible for an increase in CC-10 concentrations in
all intubated patients. We hypothesise that the differ-
ence in BAL CC-10 concentrations found in this study
between patients with late-onset VAP and non-VAP
may be attributable to the combination of infection and
p r o l o n g e d( >7d a y s )m e c h a n i c a lv e n t i l a t i o n .T h i s
hypothesis is supported by the fact that there was a sig-
nificant difference between CC-10 concentration in
patients in the non-VAP group who had been intubated
for less than 7 days and the patients in the late-onset
VAP group. However, there was no significant difference
between the early-onset VAP group and the non-VAP
group intubated for more than 7 days; thus the differ-
ence in CC-10 concentration cannot be attributed to the
intubation time alone. It is possible that other factors
related to BAL fluid influence the recovery of CC-10
levels, since the recovery of the spike was not 100%.
However, this would be the case for all BAL fluids ana-
lysed in this study.
Because of the retrospective nature of the present
study, it was not possible to measure the CC-10 BAL
levels during the patients’ stay at the ICU. The latter
factor may be of interest because some previously inves-
tigated proteins, such as procalcitonin, did not show dif-
ferences when tested once, whilst they appeared to be
promising factors in distinguishing between infection
and inflammation when tested daily [17,39]. Another
limitation of the retrospective nature of this study is
that it was not possible to analyse the potential effect of
new antibiotics administered to the patients. However,
previous studies have shown that neither antibiotics nor
corticosteroids influence the concentration of CC-10
[40,41].
Conclusions
In this study, the CC-10 concentration in BAL fluid was
not a useful predictive parameter for the diagnosis of
VAP. However, it may be an indicator for pulmonary
inflammation in general.
Key messages
￿ The CC-10 concentration in BAL fluid is not a useful
predictive parameter for the diagnosis of VAP.
￿ The CC-10 concentration in BAL fluid may be an
indicator for pulmonary inflammation in general.
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